Welcome to our dedicated page for Omada Health SEC filings (Ticker: OMDA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Omada Health, Inc. (Nasdaq: OMDA) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a virtual-first, between-visit healthcare provider focused on cardiometabolic and musculoskeletal conditions, Omada uses these filings to report on its financial condition, operations, and material events related to its digital chronic care platform.
Investors can review current reports on Form 8-K, which Omada uses to furnish press releases announcing quarterly results and other significant developments. For example, recent 8-K filings reference earnings press releases for periods in which the company reported revenue, member growth, and updates on its GLP-1-related offerings and AI capabilities. These current reports help readers connect headline financial and operational metrics to the underlying SEC record.
In addition to 8-Ks, Omada’s periodic reports on Form 10-Q and Form 10-K (accessible through the SEC and linked from this page when available) typically contain more detailed information on revenue composition, cost structure, research and development spending, and risks associated with its virtual care and GLP-1 programs. These filings are particularly relevant for understanding how Omada’s cardiometabolic and musculoskeletal programs, GLP-1 Care Tracks, and prescribing and medication management capabilities are reflected in its financial statements and risk disclosures.
Stock Titan enhances this information with AI-powered summaries that explain key points from lengthy filings, helping readers quickly identify sections related to Omada’s chronic care model, GLP-1 initiatives, and digital health operations. Users can also monitor updates to OMDA’s filings in near real time, including new 8-Ks, 10-Qs, 10-Ks, and other relevant forms, to follow how the company reports on its performance and material events over time.
Omada Health’s Chief Accounting Officer Craig Gracey reported an amended insider transaction showing a same-day option exercise and share sale. Gracey exercised 2,083 shares of Common Stock through a stock option with a $6.57 exercise price, then sold 2,083 shares in an open-market transaction at a weighted average price of $19.0118 per share.
The amendment corrects a prior Form 4 that reported the sale but inadvertently omitted the exercise, which had understated shares beneficially owned after the trade. Following the correction, Gracey directly holds 15,441 shares of Common Stock and 39,584 stock options that are exercisable at $6.57 and expire on October 23, 2034. The sale was executed under a Rule 10b5-1 trading plan adopted on March 13, 2026.
Omada Health, Inc. Chief Accounting Officer Craig Gracey reported a corrected insider transaction reflecting a same-day option exercise and share sale. The amended filing adds an exercise of 2,083 shares of common stock at $6.57 per share and the corresponding sale of 2,083 shares at $18.00 per share. Following the sale, Gracey directly holds 15,441 shares of common stock and a stock option position showing 41,667 option shares outstanding. The transactions were made under a pre-arranged Rule 10b5-1 trading plan adopted on March 13, 2026.
Omada Health, Inc. Chief Accounting Officer Craig Gracey filed an amended insider report detailing a same-day option exercise and share sale. Gracey exercised stock options to acquire 6,250 shares of common stock at $6.57 per share and sold 6,894 shares at a weighted average price of $17.4243 under a pre-arranged Rule 10b5-1 trading plan.
The amendment corrects an earlier filing that omitted the exercise leg of this exercise-and-sale transaction, which had caused reported post-transaction ownership to be understated. Following the transactions, Gracey directly holds 15,441 common shares and 43,750 stock options that remain outstanding.
Omada Health, Inc. Chief Financial Officer Steven L. Cook reported option exercises and matching share sales under a pre-arranged plan. On June 26 and June 29, he exercised stock options to acquire a total of 50,950 shares of common stock at exercise prices of $8.01 and $8.28 per share, then sold 50,950 shares in open-market transactions at weighted average prices of $19.8924 and $21.0678 per share. The filing states these were same-day exercise-and-sale transactions executed pursuant to a Rule 10b5-1 trading plan adopted on March 14, 2026. After these transactions, Cook holds 187,209 shares of Omada Health common stock directly. This Form 4/A restates an earlier Form 4 to add previously omitted exercise transactions and correct the number of securities beneficially owned following the sales.
Omada Health, Inc.’s Chief Financial Officer Steven L. Cook reported a corrected set of insider transactions combining stock option exercises with same-day share sales. On June 24–25, 2026, he exercised options for a total of 2,900 shares of common stock at $8.01 per share and sold the same number of shares in open-market trades at weighted average prices of about $19.02 per share under a Rule 10b5-1 trading plan. Following these transactions, he directly held 187,209 shares of Omada Health common stock. This Form 4/A fully restates an earlier filing by adding the previously omitted option exercises and updating the post-transaction share balance that had been understated.
Omada Health, Inc. Chief Financial Officer Steven L. Cook reported an exercise-and-sale transaction and corrected prior share totals. On June 22, 2026, he sold 17,950 shares of common stock in an open-market transaction at a weighted average price of $18.1278 per share under a Rule 10b5-1 trading plan adopted on March 14, 2026.
On the same date, he exercised stock options to acquire 11,111 shares at an exercise price of $7.68 per share and 6,839 shares at an exercise price of $8.01 per share. Following these transactions, he directly holds 187,209 shares of common stock.
The amendment states the original Form 4 omitted the exercise transactions, which caused the previously reported amount of securities beneficially owned after the sales to be understated. This Form 4/A restates the filing to include the exercises and adjusts the post-transaction ownership figures accordingly.
Omada Health, Inc. Chief Financial Officer Steven L. Cook reported an exercise-and-sale transaction involving 35,600 shares of common stock. On July 1 and July 7, 2026, he exercised stock options covering 35,600 shares at exercise prices of $7.68, $8.01 and $8.28 per share and sold the same number of shares in open-market trades.
The reported sales were 23,263 shares at a weighted average price of $22.7615 per share and 12,337 shares at a weighted average price of $23.0883 per share. Following the transactions, Cook directly holds 187,209 shares of Omada Health common stock. The filing notes that at least one sale was made under a Rule 10b5-1 trading plan adopted on March 14, 2026.
FETTER TREVOR reported acquisition or exercise transactions in this Form 4 filing.
Omada Health, Inc. director Trevor Fetter reported an equity compensation grant and an internal ownership transfer. He received 888 restricted stock units (RSUs) of Common Stock under the company’s Non-Employee Director Compensation Program in lieu of cash retainer fees, with each RSU representing one share to be settled under program terms.
Following this grant, Fetter directly holds 24,421 shares of Common Stock. Separately, 111,200 shares were transferred from a limited liability company to a family trust for which he serves as trustee and beneficiary, resulting in indirect ownership of those shares.
Omada Health, Inc. director Julie D. Klapstein reported receiving an equity grant of 649 shares of Common Stock in the form of restricted stock units. These RSUs were awarded at no cash cost per share under the company’s Non-Employee Director Compensation Program in lieu of cash retainer fees.
After this grant, Klapstein directly holds a total of 21,965 shares of Common Stock. The RSUs each represent the right to receive one share of Common Stock, with settlement occurring on a date selected by the director under the program or as otherwise provided by the plan. This is a routine, compensation-related acquisition rather than an open-market purchase.
HILLEMAN JERYL L reported acquisition or exercise transactions in this Form 4 filing.
Omada Health, Inc. director Jeryl L. Hilleman received an equity award rather than making a market purchase. She was granted 1,299 restricted stock units under the company’s Non-Employee Director Compensation Program in lieu of cash retainer fees. Each RSU represents one share of common stock, to be settled on a future date as provided by the program. Following this grant, she holds 26,519 shares of Omada Health common stock directly.